Hypericum for depression: An update of the clinical evidence

C. Stevinson, E. Ernst

    Research output: Contribution to journalArticlepeer-review

    Abstract

    This review is aimed at providing an updated evaluation of the clinical evidence regarding Hypericum perforatum (St. John's wort) as an antidepressant, based on recently published randomised controlled trials. Computerised literature searches revealed six trials published since the metaanalysis by Linde et al. (1996) [Linde, K., Ramirez, G., Mulrow, C.D., Pauls, A., Weidenhammer, W., Melchart, D., 1996. St. John's wort for depression - an overview and meta-analysis of randomised clinical trials. Br. Med. J. 313, 253-258]. The results of these studies provide further evidence that hypericum is superior to placebo in treating mild or moderate depression. However, there is still insufficient evidence to assess the efficacy of hypericum in comparison with conventional, particularly modern, antidepressants. Furthermore, there remains a lack of trials assessing long- term effects, other types of depression and different preparations and doses. It is concluded that recent clinical trials strengthen the case for hypericum as an antidepressant, but more work needs to be done to answer the remaining questions. (C) 1999 Elsevier Science B.V.
    Original languageEnglish
    Pages (from-to)501-505
    Number of pages4
    JournalEuropean Neuropsychopharmacology
    Volume9
    Issue number6
    Publication statusPublished - Dec 1999

    Keywords

    • Clinical trials
    • Depression
    • Hypericum
    • Plant extract

    Fingerprint

    Dive into the research topics of 'Hypericum for depression: An update of the clinical evidence'. Together they form a unique fingerprint.

    Cite this